Monte Rosa Therapeutics Inc. (GLUE)
NASDAQ: GLUEHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Oct 7, 4:00 PM ET · Delayed 15 min
After hours: 9.92 -2.49%
GLUE stock chart
Technical analysisKey statistics
All statistics- Market cap
- $867.64M
- EPS (TTM)
- -$1.75
- Dividend yield
- None
- 52-week range
- 7.44 – 25.77
- Day range
- 9.68 – 10.75
- Volume / Avg
- 2.08M / 1.31M
- Beta
- —
- Shares outstanding
- 85.31M
- Next earnings
- Nov 5, 2026
52-week range
GLUE stock today
Monte Rosa Therapeutics (GLUE) closed at $10.17 on Oct 7, up 3.04% (+$0.30), versus the S&P 500's 0.22% decline. Shares are 60.5% below their 52-week high of $25.77, set on Jan 8, 2026 and 36.8% above the 52-week low of $7.44, near the bottom of the past year's range. GLUE is down 35.1% year to date, underperforming the S&P 500 (+14.0%). Over the past 12 months, the stock has gained 37.8%.
Monte Rosa Therapeutics has posted a net loss over the last twelve months (EPS of -$1.75), so its P/E ratio is not meaningful. Monte Rosa Therapeutics's next earnings report is expected on Nov 5, 2026.
Summary generated from market data by MetaCap's automated system. Methodology
About Monte Rosa Therapeutics
Company profile- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- IPO year
- 2021
Earnings
Earnings history- Next report
- Nov 5, 2026
- EPS estimate
- $-0.10
Monte Rosa Therapeutics peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| SLBTSL Science Holding Limited | 1.51 | -0.66% | $846.75M | vs GLUE |
| ODTXOdyssey Therapeutics Inc. | 18.08 | -0.28% | $868.90M | vs GLUE |
| SANASana Biotechnology Inc. | 2.72 | -1.09% | $814.26M | vs GLUE |
| DNAGinkgo Bioworks Holdings Inc. Class A | 11.47 | -7.57% | $772.39M | vs GLUE |
| CADLCandel Therapeutics Inc. | 9.82 | -0.51% | $751.41M | vs GLUE |
| ATTOAttovia Therapeutics Inc. | 16.42 | -6.17% | $749.59M | vs GLUE |
| SLDBSolid Biosciences Inc. | 6.85 | -1.01% | $734.49M | vs GLUE |
| CGEMCullinan Therapeutics Inc. | 15.63 | -3.82% | $960.59M | vs GLUE |
Indexes, lists and sector
Monte Rosa Therapeutics stock FAQ
What is Monte Rosa Therapeutics's stock price today?
GLUE last traded at $10.17 as of Oct 7, 4:00 PM EDT, up 3.04% on the day. Prices are delayed at least 15 minutes.
When is Monte Rosa Therapeutics's next earnings date?
Monte Rosa Therapeutics is expected to report earnings on Thursday, November 5, 2026. Analysts expect EPS of $-0.10.
What is the GLUE 52-week high?
The 52-week high for GLUE is $25.77 and the 52-week low is $7.44. The stock is currently 60.5% below its high.